Management Team & Board of Directors
He joined Vitro Diagnostics in 1988 and directed all operations involved in the establishment of a diagnostic product line that included about 30 different purified antigen products. His direct responsibilities included research & development, manufacturing, intellectual property development and maintenance, marketing and sales. He was also responsible for the development & initial commercialization of the fertility drug VITROPIN™ as well as the cell immortalization program of the Company. He is an inventor or co-inventor of all issued and pending patents owned by the Company.
In 2000, he orchestrated the successful spin-off of the diagnostic operating division allowing the Company to focus on development of the Core technology of cell immortalization, stem cell line generation while establishing and commercializing initial the stem cell products for use in research and clinical development.
Scientific Advisory Board
Dr. Nieusma assists Vitro regarding business development and expansion of sales and marketing of existing and new products. Dr. Nieusma is especially well-connected to the pharmaceutical industry and assists the Company’s commercialization of newly developed stem cell-derived terminally differentiated cell systems for use in drug discovery, development and toxicology studies.
Dr. Rice has authored numerous peer-reviewed papers in her nearly twenty-year career as a cancer researcher in journals including “Cancer Research” and “Molecular Cancer Therapeutics.” Her research includes detailed studies of the mechanisms of cancer cell death induced by non-steroidal anti-inflammatory drugs and novel therapeutic targets for colon cancer. The latter includes pathways involved in regulating cell proliferation and cell survival.
Dr. Rice provides Vitro with technical consultation in molecular and cellular biology as needed in the development of its stem cell products and technology for application to cancer research and treatment.
Mr. Knight provides assistant in the ongoing business development activities of the Company, especially as related to turn-around to profitability and the achievement of sustained earnings growth and other relevant financial activities.